Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

"Bildungsintervention bei Tokophobie bei schwangeren Frauen" (TOKO-EDU)

5. November 2026 aktualisiert von: Delta University for Science and Technology

Changes in Tokophobia Awareness, Fear of Childbirth, Coping Strategies, and Quality of Life Following Structured Educational Sessions Among Pregnant Women: A Quasi-Experimental Single-Group Pretest-Posttest Study

This quasi-experimental single-group pretest-posttest study examined immediate within-participant differences in tokophobia awareness, fear of childbirth, reported coping-strategy use, and quality of life among 50 pregnant women attending the antenatal outpatient clinics of Soad Kafafi Hospital, 6th of October City, Giza, Egypt.

Participants attended a standardized program comprising ten face-to-face sessions delivered twice weekly over five weeks. Each session lasted approximately 45-60 minutes, including orientation, baseline assessment, educational activities, review, and post-intervention evaluation.

Outcomes were assessed using the researcher-developed Tokophobia Awareness Questionnaire (TAQ), an Arabic translation of the Fear of Childbirth Questionnaire (FCQ), the Jalowiec Coping Scale (JCS), and WHOQOL-BREF. Baseline measures were completed before educational content was delivered. Post-intervention assessment took place immediately after the final session on the same day. No longer-term follow-up was conducted.

The absence of a comparison group prevents causal attribution of the observed differences to the educational sessions.

Studienübersicht

Detaillierte Beschreibung

The study used a quasi-experimental single-group pretest-posttest design. Fifty pregnant women participated in the main study. Five separate women participated in pilot testing and were excluded from the main-study sample and analysis.

The main-study participants were divided into ten groups of five. The same educator, specializing in obstetric and gynecological health nursing, delivered the standardized program separately to each group. Other research-team members administered and collected the outcome questionnaires.

Each participant attended ten sessions over five consecutive weeks, with two sessions per week and approximately 45-60 minutes per session. Session 1 covered study orientation and procedures. Session 2 included baseline assessment, completed before delivery of educational content. Sessions 3-8 addressed tokophobia-related knowledge, childbirth preparation, coping strategies, stress management, communication, and professional and social support. Session 9 covered review and reinforcement. Session 10 included final reinforcement and immediate post-intervention assessment.

The TAQ assessed factual knowledge and awareness of tokophobia. The FCQ assessed self-reported fear of childbirth rather than establishing a clinical diagnosis of tokophobia. The JCS assessed frequency of coping-strategy use, and WHOQOL-BREF assessed self-reported quality of life across four domains.

No single primary outcome was prospectively designated. The continuous FCQ total score was prioritized for interpretation during manuscript revision. Analyses are exploratory because the study lacked a comparison group and multiple tests were conducted without adjustment.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

50

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Giza Governorate
      • Cairo, Giza Governorate, Ägypten, 12566
        • Soad Kafafi Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Pregnant women aged 18 years or older.
  • Attending the antenatal outpatient clinics at the study setting.
  • Willing to participate and provide informed consent.

Exclusion Criteria:

- Diagnosed severe or acute psychiatric disorders that could interfere with study participation.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Educational Intervention Group

Pregnant women attended a standardized ten-session educational program delivered face-to-face in groups of five, twice weekly over five weeks. Each session lasted approximately 45-60 minutes, including orientation, assessment, educational activities, review, and evaluation. Educational content addressed tokophobia awareness, childbirth preparation, coping strategies, relaxation, stress management, and available professional and social support.

A structured educational program designed to provide information about tokophobia, its causes, symptoms, and management, along with training on psychological coping strategies and supportive techniques to enhance maternal well-being.

Andere Namen:
  • Tokophobie-Bildungsprogramm

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Fear of Childbirth Questionnaire (FCQ) Total Score
Zeitfenster: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the 20-item FCQ total score from baseline to immediate post-intervention assessment. Items are scored 0-3, with positively worded items reverse-scored. Total scores range from 0 to 60; higher scores indicate greater fear of childbirth. The Arabic translation used in this study underwent preliminary linguistic and cultural adaptation.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in Tokophobia Awareness Questionnaire (TAQ) Total Score
Zeitfenster: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the researcher-developed 23-item TAQ total score from baseline to immediate post-intervention assessment. Correct responses are scored 1 and incorrect responses 0. Total scores range from 0 to 23; higher scores indicate greater factual knowledge and awareness of tokophobia.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.
Change in Jalowiec Coping Scale (JCS) Total Score
Zeitfenster: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Change in the 40-item JCS total score from baseline to immediate post-intervention assessment. Items are scored from 1 to 5, producing total scores ranging from 40 to 200. Higher scores indicate more frequent self-reported coping-strategy use.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.
Change in WHOQOL-BREF Domain Scores
Zeitfenster: Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Changes from baseline to immediate post-intervention assessment in the four WHOQOL-BREF domains: physical health, psychological health, social relationships, and environment. Each domain score is transformed to a 0-100 scale, with higher scores indicating better self-reported quality of life. The four domains are analyzed separately.

Baseline (Session 2, before educational content) and immediately after Session 10, at the end of the five-week program.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Basma W Elrefay, phd, Delta University for Science and Technology, Egypt

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

20. Februar 2025

Primärer Abschluss (Tatsächlich)

10. Mai 2025

Studienabschluss (Tatsächlich)

15. Mai 2025

Studienanmeldedaten

Zuerst eingereicht

4. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

4. April 2026

Zuerst gepostet (Tatsächlich)

13. April 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. November 2026

Zuletzt verifiziert

1. April 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • DU-TOKO-2025-01

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data (IPD) will not be made publicly available due to privacy, confidentiality, and ethical restrictions related to the study participants.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren